Table 1. Clinicopathological characteristics of patients with non-small-cell lung cancer related to PD-L1 expression and PD-L1 copy number status.
| PD-L1 expression | PD-L1 copy number status | |||||||
|---|---|---|---|---|---|---|---|---|
| Characteristic | Total (N = 654) N (%) | Positive (N = 201) N (%) | Negative (N = 453) N (%) | P value | Amplification (N = 20) N (%) | Polysomy (N = 84) N (%) | Disomy (N = 532) N (%) | P value |
| Age (years) | ||||||||
| Median (range) | 68 (23–88) | 69 (33–85) | 68 (23–88) | 0.18 | 67 (44–84) | 69 (33–85) | 68 (23–88) | 0.56 |
| Sex | ||||||||
| Male | 445 (68.0) | 159 (79.1) | 286 (63.1) | < 0.0001 | 16 (80.0) | 70 (83.3) | 349 (65.6) | 0.0021 |
| Female | 209 (32.0) | 42 (20.9) | 167 (36.9) | 4 (20.0) | 14 (16.7) | 183 (34.4) | ||
| Smoking status | ||||||||
| Never | 197 (30.1) | 34 (16.9) | 163 (36.0) | < 0.0001 | 2 (10.0) | 11 (13.1) | 177 (33.3) | < 0.0001 |
| Ever | 444 (67.9) | 163 (81.1) | 281 (62.0) | 17 (85.0) | 72 (85.7) | 345 (64.8) | ||
| Unknown | 13 (2.0) | 4 (2.0) | 9 (2.0) | 1 (5.0) | 1 (1.2) | 10 (1.9) | ||
| Histology | ||||||||
| Adenocarcinoma | 430 (65.7) | 97 (48.3) | 333 (73.5) | < 0.0001 | 5 (25.0) | 45 (53.6) | 369 (69.4) | < 0.0001 |
| Squamous cell carcinoma | 179 (27.4) | 85 (42.3) | 94 (20.8) | 11 (55.0) | 30 (35.7) | 134 (25.2) | ||
| Others | 45 (6.9) | 19 (9.4) | 26 (5.7) | 4 (20.0) | 9 (10.7) | 29 (5.4) | ||
| p-T | ||||||||
| 1 | 269 (41.1) | 74 (36.8) | 195 (43.0) | 0.36 | 3 (15.0) | 25 (29.8) | 237 (44.5) | 0.0011 |
| 2 | 283 (43.3) | 92 (45.8) | 191 (42.2) | 10 (50.0) | 43 (51.2) | 223 (41.9) | ||
| 3 | 64 (9.8) | 24 (11.9) | 40 (8.8) | 2 (10.0) | 12 (14.3) | 44 (8.3) | ||
| 4 | 38 (5.8) | 11 (5.5) | 27 (6.0) | 5 (25.0) | 4 (4.7) | 28 (5.3) | ||
| p-N | ||||||||
| 0 | 481 (73.5) | 131 (65.2) | 350 (77.3) | 0.012 | 7 (35.0) | 58 (69.0) | 405 (76.1) | < 0.001 |
| 1 | 77 (11.8) | 31 (15.4) | 46 (10.1) | 9 (45.0) | 11 (13.1) | 57 (10.7) | ||
| 2 | 89 (13.6) | 36 (17.9) | 53 (11.7) | 3 (15.0) | 14 (16.7) | 66 (12.4) | ||
| 3 | 7 (1.1) | 3 (1.5) | 4 (0.9) | 1 (5.0) | 1 (1.2) | 4 (0.8) | ||
| Pathological stage | ||||||||
| I | 416 (63.6) | 112 (55.7) | 304 (67.1) | 0.014 | 5 (25.0) | 51 (60.7) | 351 (66.0) | 0.0023 |
| II | 113 (17.3) | 39 (19.4) | 74 (16.3) | 7 (35.0) | 13 (15.5) | 91 (17.1) | ||
| III | 125 (19.1) | 50 (24.9) | 75 (16.6) | 8 (40.0) | 20 (23.8) | 90 (16.9) | ||
| Adjuvant chemotherapy | ||||||||
| Yes | 266 (40.7) | 85 (42.3) | 181 (40.0) | 0.61 | 10 (50.0) | 37 (44.0) | 210 (39.5) | 0.49 |
| No | 388 (59.3) | 116 (57.7) | 272 (60.0) | 10 (50.0) | 47 (56.0) | 322 (60.5) | ||
| Intensity of immune infiltrates | ||||||||
| High | 73 (11.2) | 38 (18.9) | 35 (7.7) | < 0.0001 | 4 (20.0) | 7 (8.3) | 61 (11.5) | 0.32 |
| Low | 581 (88.8) | 163 (81.1) | 418 (92.3) | 16 (80.0) | 77 (91.7) | 471 (88.5) | ||
| EGFR intensity | ||||||||
| High | 338 (51.7) | 138 (68.7) | 200 (44.2) | < 0.0001 | 14 (70.0) | 52 (61.9) | 267 (50.2) | 0.037 |
| Low | 316 (48.3) | 63 (31.3) | 253 (55.8) | 6 (30.0) | 32 (38.1) | 265 (49.8) | ||
| p-EGFR intensity | ||||||||
| High | 142 (21.7) | 58 (28.9) | 84 (18.5) | 0.0040 | 4 (20.0) | 27 (32.1) | 111 (20.9) | 0.075 |
| Low | 512 (78.3) | 143 (71.1) | 369 (81.5) | 16 (80.0) | 57 (67.9) | 421 (79.1) | ||
| p-Akt intensity | ||||||||
| High | 27 (4.1) | 9 (4.5) | 18 (4.0) | 0.83 | 1 (5.0) | 3 (3.6) | 23 (4.3) | 0.82 |
| Low | 627 (95.9) | 192 (95.5) | 435 (96.0) | 19 (95.0) | 81 (96.4) | 509 (95.7) | ||
| Mutant EGFR expression | ||||||||
| Positive | 132 (20.2) | 25 (12.4) | 107 (23.6) | 0.0010 | 0 | 12 (14.3) | 114 (21.4) | 0.013 |
| Negative | 522 (79.8) | 176 (87.6) | 346 (76.4) | 20 (100) | 72 (85.7) | 418 (78.6) | ||
| ALK expression | ||||||||
| Positive | 10 (1.5) | 5 (2.5) | 5 (1.1) | 0.19 | 0 | 1 (1.2) | 9 (1.7) | 1.0 |
| Negative | 644 (98.5) | 196 (97.5) | 448 (98.9) | 20 (100) | 83 (98.8) | 523 (98.3) | ||
Abbreviations: EGFR, epidermal growth factor receptor; p-EGFR, phospho-EGFR; p-Akt, phospho-Akt; ALK, anaplastic lymphoma kinase.
P values were obtained using the Mann–Whitney U test, the Kruskal–Wallis test, and the Fisher's exact test.
Fluorescence in situ hybridization analyses were not successful in 18 patients because of insufficient signaling intensity or loss of cores.